Clinical Trial

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Study acronym: Pembro-CORE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-04-08; most recent amendment 2024-08-21.
Status change: Not Yet Recruiting → Recruiting 2024-08-21
Trial Details
NCT Number NCT04838652
Lead Sponsor University of Cologne
Conditions Classical Hodgkin Lymphoma
Enrollment 29 participants
Start Date 2024-03-05
Primary Completion 2026-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2024-08-23